Skip to content

← All developments

CMS Newsroom · May 3, 2026 · Primary source

CMS Extends Deadlines for GENEROUS Model Applications for Drug Manufacturers and States

Score 80PRIMARYguidanceCMS

What the document says

CMS issued a news alert announcing an extension of the application deadline for drug manufacturers to participate in the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model. The original deadline of April 30, 2026, has been extended to June 11, 2026. CMS attributed the extension to overwhelming interest from prescription drug manufacturers.

The extension is specifically intended to provide additional time for small to mid-sized drug manufacturers to engage with the CMS Innovation Center, review participation information, and prepare their applications. The alert also references a separate application deadline for states, though the source text does not detail the state deadline or its extension terms.

The GENEROUS Model, whose full name is GENErating cost Reductions fOr U.S. Medicaid, is administered through the CMS Innovation Center and is focused on generating cost reductions within the Medicaid program. No further model parameters, payment structures, or statutory authorities are described in the available source text.

What this may mean

Drug manufacturers, particularly small to mid-sized companies, and state Medicaid agencies considering participation in the GENEROUS Model may need to revise internal timelines to account for the new June 11, 2026 application deadline. Organizations that had deprioritized engagement with the CMS Innovation Center before the original April 30 deadline may now want to reconsider whether renewed outreach is warranted.

Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.

Related items